TYK Medicines, Inc. (Stock Code: 2410) has announced that the China Securities Regulatory Commission (CSRC) recently issued a filing notice in relation to its H Share Full Circulation application. According to the notice, the conversion of 4,608,000 unlisted shares held by one shareholder into the same number of H shares has been completed as part of the company’s plan.

Following listing approval from The Stock Exchange of Hong Kong Limited, these converted H shares will be traded on the Main Board. The filing notice from the CSRC will remain valid for 12 months from the date of approval. Details of the implementation plan for the H Share Full Circulation have yet to be finalized.

Further announcements on the progress of the H Share Full Circulation will be made in compliance with relevant regulatory requirements. The completion of the H Share Full Circulation remains subject to applicable procedures of the Stock Exchange and other regulatory authorities.